Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Not yet recruiting 2Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Breast 1

Conditions

Prostatic Neoplasms 1Oligo-metastatic Prostate Carcinoma 1Neoplasm Metastasis 1

Interventions

Gemcitabine 13Radiotherapy 12Androgen Antagonists 12Specimen Handling 11Magnetic Resonance Spectroscopy 10pembrolizumab 9Nivolumab 8toripalimab 7darolutamide 7Drug Therapy 7Radiosurgery 6Docetaxel 6Cystectomy 6enzalutamide 5apalutamide 5Mitomycin 5Cisplatin 5Axitinib 5Abiraterone Acetate 5disitamab vedotin 4cabozantinib 4abiraterone 4Pluvicto 4Cyclophosphamide 4tislelizumab 3lenvatinib 3fludarabine 3cemiplimab 3Sunitinib 3Standard of Care 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Hormones × Genitourinary × Clear all
NCT06660862 2026-01-08

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

University of Chicago

Phase 4 Not yet recruiting
80 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT06198387 2024-01-10

Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer

Changhai Hospital

Phase NA Not yet recruiting
30 enrolled
Genitourinary

Oligo-metastatic Prostate Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡